Subject(s)
COVID-19 , Coronavirus Infections , COVID-19/therapy , Humans , Immunization, Passive , SARS-CoV-2 , COVID-19 SerotherapyABSTRACT
Campylobacter jejuni isolates (n = 533) from domestic cases diagnosed in Finland during a 3-month peak period were studied. The highest rate was observed among those 70-74 years of age. Domestic C. jejuni isolates were especially frequent in the eastern districts. Six serotypes covered 61% of all C. jejuni isolates.
Subject(s)
Campylobacter Infections/epidemiology , Campylobacter jejuni/isolation & purification , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Campylobacter jejuni/classification , Campylobacter jejuni/pathogenicity , Child , Female , Finland/epidemiology , Humans , Male , Middle Aged , Serotyping , Sex DistributionABSTRACT
The in vitro susceptibilities of 678 Campylobacter jejuni and Campylobacter coli strains isolated from stool samples of the same number of Finnish subjects were studied. A total of 523 patients, representing inhabitants from throughout Finland, had not traveled abroad within the 2 weeks prior to becoming ill, whereas 155 persons had presumably acquired their infections abroad. The antimicrobial agents studied were erythromycin, ciprofloxacin, levofloxacin, trovafloxacin, and moxifloxacin. The MICs of these antimicrobial agents were determined by the agar dilution method. The growth of all domestic isolates was inhibited by erythromycin at concentrations of 4 microg/ml, and for these isolates the fluoroquinolone MICs at which 90% of isolates are inhibited (MIC(90)s) ranged from 0.06 to 0.5 microg/ml. For the foreign isolates, the erythromycin MIC(90) was still low (4 microg/ml), but their susceptibilities to fluoroquinolones were clearly reduced (MIC(90)s, 8 to 64 microg/ml). Of the four different fluoroquinolones studied, ciprofloxacin was the least active (MIC(90), 64 micro g/ml).
